ProCE Banner Activity

MURANO 5-Yr Analysis: Fixed-Duration Venetoclax + Rituximab vs Bendamustine + Rituximab in R/R CLL

Slideset Download
Conference Coverage
5-year analysis of the phase III MURANO trial continued to demonstrate the efficacy of venetoclax + rituximab in patients with relapsed/refractory CLL.

Released: December 17, 2020

Expiration: December 16, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology